Thank you 🙏

Thanks to postdoctoral fellow Dr. Jiao Li who led this study, contributions of all coauthors, our editor and reviewers whose feedback strengthened our manuscript and to funding sources who supported this work. /end

Our study provides further mechanistic evidence that tRCC is genetically and transcriptionally distinct from other kidney cancers. We hope this will be another step forward towards developing the first therapies specifically targeting the unique biology of tRCC. #rarecancer 4/

This profile confers selective dependencies in OXPHOS-dep. tRCC cells. e.g tRCCs show selective dep on EGLN1. Inhibiting EGLN1 stabilizes HIF-1α, leading to glycolytic reprogramming. EGLN inhibitors, approved for anemia treatment, could perhaps be explored for tRCC & other OXPHOS-high cancers 💊. 3/

Unexpectedly, unlike ccRCC (most common kidney cancer) and other RCCs that are highly glycolytic, we show that tRCC prefers mitochondrial respiration. 2/